SU438419A1 - METHOD OF OBTAINING COLLOIDAL SOLUTION ITTRIEM-90 - Google Patents

METHOD OF OBTAINING COLLOIDAL SOLUTION ITTRIEM-90

Info

Publication number
SU438419A1
SU438419A1 SU1245927A SU1245927A SU438419A1 SU 438419 A1 SU438419 A1 SU 438419A1 SU 1245927 A SU1245927 A SU 1245927A SU 1245927 A SU1245927 A SU 1245927A SU 438419 A1 SU438419 A1 SU 438419A1
Authority
SU
USSR - Soviet Union
Prior art keywords
solution
yttrium
colloidal solution
ittriem
obtaining colloidal
Prior art date
Application number
SU1245927A
Other languages
Russian (ru)
Original Assignee
Н. Б. Михеев, М. А. Грачева , А. И. Журба Институт биофизики
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Н. Б. Михеев, М. А. Грачева , А. И. Журба Институт биофизики filed Critical Н. Б. Михеев, М. А. Грачева , А. И. Журба Институт биофизики
Priority to SU1245927A priority Critical patent/SU438419A1/en
Application granted granted Critical
Publication of SU438419A1 publication Critical patent/SU438419A1/en

Links

Landscapes

  • Colloid Chemistry (AREA)

Description

1one

Изобретение относитс  к получению медицинских радиоактивных препаратов.This invention relates to the manufacture of medical radioactive drugs.

Известен способ получени  коллоидного раствора с иттрием-90, заключающийс  в смешении силиката и фосфата натри , иттри  хлористого и иттри -90 и полиглюкина.A known method for producing a colloidal solution with yttrium-90 consists in mixing silicate and sodium phosphate, yttrium chloride and yttri-90 and polyglucin.

Дл  увеличени  срока действи  целевого продукта на облучаемые ткани предлагаетс  к раствору хлористого иттри , содержащему иттрий-90 и желатиноль, добавл ть раствор глюкозы и едкого кали , а полученную смесь вливать в раствор олеата кали  с гидрофосфагом натри  и желатинолем.To increase the duration of the effect of the target product on the irradiated tissue, it is proposed to add a solution of glucose and caustic potassium to a solution of yttrium chloride containing yttrium-90 and gelatinol, and pour the resulting mixture into a solution of potassium oleate with sodium hydrogen phosphide and gelatinol.

Пример. Дл  получени  коллоидного раствора и суспензии олеата иттри  с иттрием-90 используют стерильные растворы соли иттри , содержащей иттрий-90 (1), соли олеиновой кислоты (2) и стабилизатора (З).Дл  получени  раствора к 1,5 мл желатинола добавл ют 1 мл раствора хлористого иттри  с иттрием-90, имеющего концентрацию 10 мг/мл. Дл  приготовлени  раствора 2 к 1,35 мл желатинол  добавл ют 0,25 мл раствор   гидрофосфата натри  (конц. 20 мг/мл Na2MPO4) и 0,9 мл раствора олеата кали  в этиловом спирте (конц. 0,17 г/мл). Раствор 3 получают, смещива  0,4 мл 0,5 н. КОН с 5 мл 40%-ного раствора глюкозы.Example. To obtain a colloidal solution and a suspension of yttrium oleate with yttrium-90, sterile solutions of yttrium salt containing yttrium-90 (1), oleic acid salts (2) and stabilizer (H) are used. To obtain a solution, add 1.5 ml of gelatinol ml of a solution of yttrium chloride with yttrium-90, having a concentration of 10 mg / ml. To prepare a solution of 2 to 1.35 ml of gelatinol, 0.25 ml of sodium hydrogen phosphate solution (conc. 20 mg / ml Na2MPO4) and 0.9 ml of potassium oleate in ethanol (conc. 0.17 g / ml) are added. Solution 3 is obtained by displacing 0.4 ml 0.5 n. KOH with 5 ml of 40% glucose solution.

Растворы 1 и 2 стерилизуют в автоклаве при одной избыточной атмосфере в течениеSolutions 1 and 2 are sterilized in an autoclave at one excess atmosphere for

18 мин. Раствор 3 стерилизуют фильтрованием через бактериальный фильтр. Коллоидный раствор олеата иттри  с иттрием-90 получают непосредственно перед использованием. Дл  этого раствор 3 с помощью щприца смещивают с раствором 1. Полученный раствор с помощью шприца вливают в раствор 2.18 min Solution 3 is sterilized by filtration through a bacterial filter. A colloidal solution of yttrium oleate with yttrium-90 is prepared immediately before use. To do this, solution 3 is shifted with a syringe with solution 1. The resulting solution is poured into a solution 2 with a syringe.

Коллоидный раствор олеата иттри  с игтрием-90 пригоден дл  использовани  в течение двух часов после его приготовлени . Тот же раствор, выдержанный в течение 20 час или более, переходит в устойчивую микросуспензию с размерами частиц около 100-10 мк.Yttrium oleate with igthrium-90 colloidal solution is suitable for use within two hours after its preparation. The same solution, aged for 20 hours or more, becomes a stable microsuspension with a particle size of about 100-10 microns.

Полученный коллоидный раствор и микросуспензи  имеют удельную активность 2- 4 мкюри/мл и кислотность 8-9,5 рН. Содержание иттри  в ионном состо нии - менее 1-2%.The resulting colloidal solution and microsuspensions have a specific activity of 2-4 micron / ml and an acidity of 8-9.5 pH. The content of yttrium in the ionic state is less than 1-2%.

При необходимости перед использованием препараты могут быть разбавлены в любом отнощении 40%-ным стерильным раствором глюкозы. В результате первичных лабораторных испытаний установлено, что при внутримышечном введении оба препарата остаютс  на месте введени , а при внутривенном введении коллоидного раствора олеат иттри , более 80%, захватываетс  органами ретикулоэндотелиальной системы. . , -. ., 3 Предмет изобретени  Способ получени  коллоидного раствора с иттрием-90 путем смешени  раствора хлористого иттри  и иттри -90 с раствором соли 5 щелочного металла и стабилизатора, отличающийс  тем, что, с целью увеличени  4 срока действи  Целевого продукта на облучаемые ткани, к раствору хлористого иттри , содержащему иттрий-90 и желатиноль, добавл ют раствор глюкозы и едкого кали , полученную смесь вливают в раствор олеата кали  с гидрофосфатом натри  и желатинолем. If necessary, before use, the preparations can be diluted in any ratio with 40% sterile glucose solution. As a result of the initial laboratory tests, it was established that with intramuscular administration, both drugs remain at the site of administration, and with intravenous administration of a yttrium oleate colloidal solution, more than 80%, are captured by the organs of the reticuloendothelial system. . , -. ., 3 The subject of the invention. A method of obtaining a colloidal solution with yttrium-90 by mixing a solution of yttrium chloride and yttrium-90 with a solution of alkali metal salt 5 and a stabilizer, characterized in that, in order to increase the 4 times the duration of the Target Product on the irradiated tissue, yttrium chloride containing yttrium-90 and gelatinol is added to a solution of glucose and caustic potash, the mixture is poured into a solution of potassium oleate with sodium hydrogen phosphate and gelatinol.

SU1245927A 1968-05-31 1968-05-31 METHOD OF OBTAINING COLLOIDAL SOLUTION ITTRIEM-90 SU438419A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU1245927A SU438419A1 (en) 1968-05-31 1968-05-31 METHOD OF OBTAINING COLLOIDAL SOLUTION ITTRIEM-90

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU1245927A SU438419A1 (en) 1968-05-31 1968-05-31 METHOD OF OBTAINING COLLOIDAL SOLUTION ITTRIEM-90

Publications (1)

Publication Number Publication Date
SU438419A1 true SU438419A1 (en) 1974-08-05

Family

ID=20442627

Family Applications (1)

Application Number Title Priority Date Filing Date
SU1245927A SU438419A1 (en) 1968-05-31 1968-05-31 METHOD OF OBTAINING COLLOIDAL SOLUTION ITTRIEM-90

Country Status (1)

Country Link
SU (1) SU438419A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001340A1 (en) * 1987-08-17 1989-02-23 The United States Of America, As Represented By Th Method for treating malignancy and autoimmune disorders in humans

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001340A1 (en) * 1987-08-17 1989-02-23 The United States Of America, As Represented By Th Method for treating malignancy and autoimmune disorders in humans

Similar Documents

Publication Publication Date Title
DE3240177C2 (en)
DE2723878C2 (en)
DE2814038C3 (en) Material that can be labeled with a radionuclide for radioactive testing
DE2655801A1 (en) METHOD FOR PRODUCING A MASS OF LOADED CELLS SUSPENDED IN A PHYSIOLOGICAL SOLUTION
US2411897A (en) Pharmaceutical solution
DE2519005A1 (en) METHOD FOR DIAGNOSTIC VISIBILITY OF NEOPLASTIC TISSUE
SU438419A1 (en) METHOD OF OBTAINING COLLOIDAL SOLUTION ITTRIEM-90
Khato et al. Carrier activity of sonicated small liposomes containing melphalan to regional lymph nodes of rats
DE2659799C2 (en) Iron(III) hydroxide-dextrin-carboxylic acid complex and process for its preparation as well as a therapeutic preparation containing an iron(III) hydroxide-dextrin-citric acid complex
CH652599A5 (en) Method for producing colloidal physiological degradable, human serum albumin containing products and their use.
DE2639849A1 (en) PROCESS FOR THE PREPARATION OF STABLE PREPARATIONS OF WATER-SOLUBLE SALTS OF DEHYDROEPIANDROSTERONE SULPHATE FOR PARENTERAL ADMINISTRATION
DE2224182C2 (en) Process for the preparation of an injectable, aqueous, stable emulsion capable of oxygen transport
DE2656333C2 (en) Process for the production of liposomes which contain medicinal substances
EP0472772A1 (en) Process for the preparation of vital drug-laden human erythrocytes
US3553148A (en) Method of making a calcium gel and the product of this method
WO2000056325A2 (en) Ibuprofen solution
RU2709181C1 (en) Method of producing gels for medical purposes based on l-cysteine, silver nitrate and polyvinyl alcohol
DE2262427B2 (en) Immunostimulating agent
DE960579C (en) Process for the production of a heat-sterilizable adrenocorticotropin preparation
DE2160009A1 (en) Method and apparatus for producing an injectable carrier for radioisotopes
DE1086012B (en) Process for the production of protracted vitamin B preparations
US4088759A (en) Injectable pharmaceutical solutions
JP3773210B2 (en) Trehalose-containing fat emulsion
USRE27240E (en) Therapeutic preparation of iron
DE3888404T2 (en) Method for suppressing the thermal degradation of urokinase.